Editas Medicine Statistics

Total Valuation

Editas Medicine has a market cap or net worth of $158.49 million. The enterprise value is -$68.11 million.

Market Cap	158.49M
Enterprise Value	-68.11M

Important Dates

The next estimated earnings date is Monday, March 3, 2025, before market open.

Earnings Date	Mar 3, 2025
Ex-Dividend Date	n/a

Share Statistics

Editas Medicine has 82.55 million shares outstanding. The number of shares has increased by 12.94% in one year.

Current Share Class	82.55M
Shares Outstanding	82.55M
Shares Change (YoY)	+12.94%
Shares Change (QoQ)	+0.21%
Owned by Insiders (%)	0.40%
Owned by Institutions (%)	63.25%
Float	82.22M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.55
Forward PS	4.41
PB Ratio	0.90
P/TBV Ratio	0.90
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.75, with a Debt / Equity ratio of 0.22.

Current Ratio	3.75
Quick Ratio	3.67
Debt / Equity	0.22
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -78.56% and return on invested capital (ROIC) is -46.89%.

Return on Equity (ROE)	-78.56%
Return on Assets (ROA)	-34.32%
Return on Invested Capital (ROIC)	-46.89%
Return on Capital Employed (ROCE)	-89.54%
Revenue Per Employee	$233,053
Profits Per Employee	-$794,611
Employee Count	265
Asset Turnover	0.15
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -75.85% in the last 52 weeks. The beta is 1.94, so Editas Medicine's price volatility has been higher than the market average.

Beta (5Y)	1.94
52-Week Price Change	-75.85%
50-Day Moving Average	1.44
200-Day Moving Average	3.47
Relative Strength Index (RSI)	55.72
Average Volume (20 Days)	5,798,360

Short Selling Information

The latest short interest is 17.09 million, so 20.70% of the outstanding shares have been sold short.

Short Interest	17.09M
Short Previous Month	19.15M
Short % of Shares Out	20.70%
Short % of Float	20.78%
Short Ratio (days to cover)	6.83

Income Statement

In the last 12 months, Editas Medicine had revenue of $61.76 million and -$210.57 million in losses. Loss per share was -$2.56.

Revenue	61.76M
Gross Profit	-158.43M
Operating Income	-228.52M
Pretax Income	-193.45M
Net Income	-210.57M
EBITDA	-222.63M
EBIT	-228.52M
Loss Per Share	-$2.56

Full Income Statement

Balance Sheet

The company has $265.09 million in cash and $38.49 million in debt, giving a net cash position of $226.60 million or $2.75 per share.

Cash & Cash Equivalents	265.09M
Total Debt	38.49M
Net Cash	226.60M
Net Cash Per Share	$2.75
Equity (Book Value)	175.63M
Book Value Per Share	2.13
Working Capital	198.79M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$181.76 million and capital expenditures -$9.59 million, giving a free cash flow of -$191.36 million.

Operating Cash Flow	-181.76M
Capital Expenditures	-9.59M
Free Cash Flow	-191.36M
FCF Per Share	-$2.32

Full Cash Flow Statement

Margins

Gross Margin	-256.53%
Operating Margin	-370.02%
Pretax Margin	-340.96%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Editas Medicine does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.94%
Shareholder Yield	-12.94%
Earnings Yield	-132.86%
FCF Yield	-120.73%

Analyst Forecast

The average price target for Editas Medicine is $8.08, which is 320.83% higher than the current price. The consensus rating is "Buy".

Price Target	$8.08
Price Target Difference	320.83%
Analyst Consensus	Buy
Analyst Count	14
Revenue Growth Forecast (5Y)	-1.70%
EPS Growth Forecast (5Y)	-7.24%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Editas Medicine has an Altman Z-Score of -5.28 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-5.28
Piotroski F-Score	3